Find Binimetinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

0

JDMF

0

KDMF

0

VMF

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

South Africa

0

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

MARKET PLACE

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 606143-89-9, Mek162, Arry-162, Mektovi, Arry-438162, Mek-162
Molecular Formula
C17H15BrF2N4O3
Molecular Weight
441.2  g/mol
InChI Key
ACWZRVQXLIRSDF-UHFFFAOYSA-N
FDA UNII
181R97MR71

Binimetinib
Binimetinib is an orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. Inhibition of MEK1/2 prevents the activation of MEK1/2 dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and an inhibition in production of various inflammatory cytokines including interleukin-1, -6 and tumor necrosis factor. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.
1 2D Structure

Binimetinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
6-(4-bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
2.1.2 InChI
InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
2.1.3 InChI Key
ACWZRVQXLIRSDF-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO
2.2 Other Identifiers
2.2.1 UNII
181R97MR71
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Mek162

2. Mektovi

2.3.2 Depositor-Supplied Synonyms

1. 606143-89-9

2. Mek162

3. Arry-162

4. Mektovi

5. Arry-438162

6. Mek-162

7. 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzimidazole-6-carboxamide

8. Arry 438162

9. Arry 162

10. Binimetinib (mek-162)

11. Nvp-mek162

12. Mek162 (arry-162, Arry-438162)

13. Mfcd22124525

14. Binimetinib (mek162, Arry-162, Arry-438162)

15. 181r97mr71

16. 6-(4-bromo-2-fluoroanilino)-7-fluoro-n-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide

17. 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzo[d]imidazole-6-carboxamide

18. 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzo[d]imidazole-6-carboxamide.

19. 5-(4-bromo-2-fluoroanilino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzimidazole-6-carboxamide

20. Binimetinib [usan:inn]

21. Binimetinibum

22. Unii-181r97mr71

23. 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzimidazole-6-carboxamide

24. 5-(4-bromo-2-fluorophenylamino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzo(d)imidazole-6-carboxamide

25. 5-(4-bromo-2-fluorophenylamino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzo[d]imidazole-6-carboxamide

26. Mektovi (tn)

27. Arry-162; Arry-438162; Mek 162; Arry 162; Arry 438162

28. Binimetinib; Mek162

29. Mek162(binimetinib)

30. Binimetinib [mi]

31. Binimetinib (mek162)

32. Binimetinib [inn]

33. Binimetinib [jan]

34. Binimetinib (jan/usan)

35. Binimetinib [usan]

36. Binimetinib [who-dd]

37. Mls006011180

38. Schembl570088

39. Gtpl7921

40. Chembl3187723

41. Amy9056

42. Binimetinib [orange Book]

43. Dtxsid70209422

44. Arry-162,mek-162

45. Chebi:145371

46. Bdbm520649

47. Hms3652j14

48. Hms3747g09

49. Bcp06780

50. Ex-a1024

51. Nsc764042

52. Nsc788187

53. Nsc799361

54. S7007

55. Zinc38460704

56. Akos026750517

57. Ccg-269133

58. Cs-0627

59. Db11967

60. Nsc-764042

61. Nsc-788187

62. Nsc-799361

63. Sb16501

64. Ncgc00345804-01

65. Ncgc00345804-10

66. 1073666-70-2

67. 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-n-(2-hydroxyethoxy)-1-methylbenzimidazole-6-carboxamide

68. 6-(4-bromo-2-fluorophenylamino)-7-fluoro-n-(2-hydroxyethoxy)-3-methyl-3h-benzo[d]imidazole-5-carboxamide

69. Ac-29023

70. As-16706

71. Da-35030

72. Hy-15202

73. Smr004702949

74. Sy284756

75. Cas:606143-89-9;mek162

76. Ft-0697088

77. Sw219910-1

78. D10604

79. Binimetinib;mek-162; Arry-162;arry-438162

80. J-516581

81. Q19903515

82. Us11147816, Binimetinib (arry-162, Arry-438162)

83. 1h-benzimidazole-6-carboxamide, 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-

84. 5-((4-bromo-2-fluorophenylamino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzo (d) Imidazole-6-carboxamide

85. 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-1,3-benzodiazole-6-carboxamide

86. 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzimidazole-6-carboxami

87. 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3h-benzoimidazole-5-carboxylic Acid (2-hydroxyethyoxy)-amide

88. 6-[(4-bromo-2-fluorophenyl)amino]-7-fluoro-n-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide

89. N-(2-hydroxyethoxy)-4-fluoro-5-(2-fluoro-4-bromophenylamino)-1-methyl-1h-benzoimidazole-6-carboxamide

90. Qo7

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 441.2 g/mol
Molecular Formula C17H15BrF2N4O3
XLogP33.1
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count7
Rotatable Bond Count6
Exact Mass440.02956 g/mol
Monoisotopic Mass440.02956 g/mol
Topological Polar Surface Area88.4 Ų
Heavy Atom Count27
Formal Charge0
Complexity521
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.


Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.


Treatment of colorectal carcinoma


Treatment of melanoma


5 Pharmacology and Biochemistry
5.1 Pharmacology

Binimetinib is a MEK inhibitor. MEK is an enzyme that regulates the biosynthesis of the inflammatory cytokines TNF, IL-6 and IL-1. MEK inhibitors interfere with these biosynthetic processes. It is a chemotherapeutic agent that has anti-tumor activity,.


5.2 ATC Code

L01EE03


L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01E - Protein kinase inhibitors

L01EE - Mitogen-activated protein kinase (mek) inhibitors

L01EE03 - Binimetinib


5.3 Absorption, Distribution and Excretion

Absorption

Following oral administration in a pharmacokinetic study, at least 50% of the binimetinib dose was absorbed with a median time to maximum concentration (Tmax) of 1.6 hours. The administration of a single dose of MEKTOVI 45 mg with a high-fat, high-calorie meal (consisting of approximately 150 calories from protein, 350 calories from carbohydrate, and 500 calories from fat) in healthy subjects had no effect on binimetinib exposure.


Route of Elimination

Following a single oral dose of 45 mg radiolabeled binimetinib in healthy subjects, 62% (32% unchanged) of the administered dose was recovered in the feces while 31% (6.5% unchanged) was recovered in the urine.


Volume of Distribution

The geometric mean (CV%) of apparent volume of distribution of binimetinib is 92 L (45%)


Clearance

20.2 L/h (24%)


5.4 Metabolism/Metabolites

The primary metabolic pathway is glucuronidation with UGT1A1 contributing up to 61% of the binimetinib metabolism. Other pathways of binimetinib metabolism include N-dealkylation, amide hydrolysis, and loss of ethane-diol from the side chain. The active metabolite M3 produced by CYP1A2 and CYP2C19 represents 8.6% of the binimetinib exposure. Following a single oral dose of 45 mg radiolabeled binimetinib, approximately 60% of the circulating radioactivity AUC in plasma was attributable to binimetinib.


5.5 Biological Half-Life

The mean (CV%) terminal half-life (t1/2) of binimetinib is 3.5 hours (28.5%).


5.6 Mechanism of Action

Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. The inhibition of MEK1/2 prevents the activation of MEK1/2-dependent effector proteins and transcription factors. This process can result in the inhibition of growth factor-mediated cell signaling. This may lead to the inhibition of tumor cell proliferation and an inhibition in the production of various inflammatory cytokines including interleukin-1, -6 and tumor necrosis factor. MEK1/2 are themselves threonine and tyrosine kinases that possess a dual specificity. They subsequently contribute critically to the activation of the RAS/RAF/MEK/ERK pathway and are typically upregulated in a number of different tumor cell types.


API SUPPLIERS

read-more
read-more

01

Omgene Life Sciences Pvt. Ltd

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Omgene Company Banner

02

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Sampe
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Sampe
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WCarrow-down NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank

03

Alembic Pharmaceuticals Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Sampe
Not Confirmed
arrow

Alembic Pharmaceuticals Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Sampe
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WCarrow-down NDC KDMF VMF Others AUDIT arrow-down
blank

04

Country

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Sampe
Not Confirmed
arrow

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Sampe
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

05

Country

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Sampe
Not Confirmed
arrow

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Sampe
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

06

Icrom

Italy

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Sampe
Not Confirmed
arrow
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

PCC
Not Confirmed

01

PCC
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2022-05-13

Pay. Date : 2022-04-19

DMF Number : 36600

Submission : 2021-12-30

Status : Active

Type : II

blank

02

PCC
Not Confirmed

02

PCC
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2022-02-15

Pay. Date : 2022-01-06

DMF Number : 36434

Submission : 2021-12-09

Status : Active

Type : II

blank

03

Valary Lab Private Limited

Country

USDMF

arrow
PCC
Not Confirmed

03

Valary Lab Private Limited

Country
arrow
PCC
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 40805

Submission : 2024-11-27

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-moreread-more

01

Bioprocess International Europe
Not Confirmed
arrow
arrow
Bioprocess International Europe
Not Confirmed

Binimetinib

Date of Issue : 2025-08-22

Valid Till : 2028-08-21

Written Confirmation Number : WC-0082

Address of the Firm : Karakhadi, Plot No. 842-843, At - Karakhdi, Tal. - Padra, Dist -Vadodara, Gujara...

blank

02

Bioprocess International Europe
Not Confirmed
arrow
arrow
Bioprocess International Europe
Not Confirmed

Binimetinib IH

Date of Issue : 2025-09-19

Valid Till : 2028-05-05

Written Confirmation Number : WC-0349

Address of the Firm : Unit-II, Sy. Nos. 50, 53, 53/A, 54 & 54/A,Kardanur (Village), Patancheru (Mandal...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

Bioprocess International Europe
Not Confirmed
arrow
arrow
Bioprocess International Europe
Not Confirmed

BINIMETINIB

NDC Package Code : 54893-0119

Start Marketing Date : 2021-12-09

End Marketing Date : 2027-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

02

Valary Lab Private Limited

Country
Bioprocess International Europe
Not Confirmed
arrow

Valary Lab Private Limited

Country
arrow
Bioprocess International Europe
Not Confirmed

BINIMETINIB

NDC Package Code : 81955-0022

Start Marketing Date : 2018-06-27

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Flag India
Digital Content Digital Content

Binimetinib

About the Company : Omgene Life Sciences Pvt. Ltd. is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integ...

Omgene Life Sciences Pvt. Ltd. is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integrated company, we focus on developing high-quality formulations based on in-house-produced actives. With GMP-certified facilities and partnerships with contract manufacturers, we excel in formulation development for injectables, lyophilized injectables, complex generics, and oral peptide delivery systems, ensuring affordable, top-quality medicines. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Omgene Company Banner

02

Bioprocess International Europe
Not Confirmed
arrow
arrow
Bioprocess International Europe
Not Confirmed

Binimetinib

About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...

Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates.
blank

03

Icrom

Italy
Bioprocess International Europe
Not Confirmed
arrow

Icrom

Italy
arrow
Bioprocess International Europe
Not Confirmed

Binimetinib

About the Company : ICROM is specialized in the manufacturing and contract manufacturing of Active Pharmaceutical Ingredients (APIs) and GMP intermediates. ICROM is the partner of choice for pharmaceu...

ICROM is specialized in the manufacturing and contract manufacturing of Active Pharmaceutical Ingredients (APIs) and GMP intermediates. ICROM is the partner of choice for pharmaceutical outsourcing. Since 1969, ICROM is specialized in the manufacturing and contract manufacturing of Active Pharmaceutical Ingredients (APIs) and GMP intermediates. Thanks to the extensive experience and strong know-how, ICROM is the ideal partner for designing and tailoring projects upon customers’ needs.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Annual Reports

read-more
read-more

01

Brand Name : Mektovi

Binimetinib

arrow
BPI Europe
Not Confirmed

Brand Name : Mektovi

U.S.A
arrow
BPI Europe
Not Confirmed

Binimetinib

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 49

2018 Revenue in Millions : 0

Growth (%) : New launch

blank

02

Brand Name : Mektovi

Binimetinib

arrow
BPI Europe
Not Confirmed

Brand Name : Mektovi

U.S.A
arrow
BPI Europe
Not Confirmed

Binimetinib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 142

2019 Revenue in Millions : 49

Growth (%) :

blank

03

Brand Name : Mektovi

Binimetinib

arrow
BPI Europe
Not Confirmed

Brand Name : Mektovi

U.S.A
arrow
BPI Europe
Not Confirmed

Binimetinib

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 155

2020 Revenue in Millions : 142

Growth (%) : 9

blank

04

Brand Name : Mektovi

Binimetinib

arrow
BPI Europe
Not Confirmed

Brand Name : Mektovi

Japan
arrow
BPI Europe
Not Confirmed

Binimetinib

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 14

2020 Revenue in Millions : 0

Growth (%) : 100

blank

05

Brand Name : Mektovi

Binimetinib

arrow
BPI Europe
Not Confirmed

Brand Name : Mektovi

Japan
arrow
BPI Europe
Not Confirmed

Binimetinib

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 19

2021 Revenue in Millions : 14

Growth (%) : 34

blank

06

Brand Name : Mektovi

Binimetinib

arrow
BPI Europe
Not Confirmed

Brand Name : Mektovi

U.S.A
arrow
BPI Europe
Not Confirmed

Binimetinib

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 176

2021 Revenue in Millions : 155

Growth (%) : 14

blank

07

Brand Name : Mektovi

Binimetinib

arrow
BPI Europe
Not Confirmed

Brand Name : Mektovi

U.S.A
arrow
BPI Europe
Not Confirmed

Binimetinib

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 174

2022 Revenue in Millions : 176

Growth (%) : -1

blank

08

Brand Name : Mektovi

Binimetinib

arrow
BPI Europe
Not Confirmed

Brand Name : Mektovi

Japan
arrow
BPI Europe
Not Confirmed

Binimetinib

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 18

2022 Revenue in Millions : 19

Growth (%) : 4

blank

09

Brand Name : Braftovi/Mektovi

Encorafenib, Binimetinib

arrow
BPI Europe
Not Confirmed

Brand Name : Braftovi/Mektovi

U.S.A
arrow
BPI Europe
Not Confirmed

Encorafenib, Binimetinib

Main Therapeutic Indication : Oncology

Currency : USD

2024 Revenue in Millions : 607

2023 Revenue in Millions : 477

Growth (%) : 27

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 606143-89-9 / Binimetinib API manufacturers, exporters & distributors?

Binimetinib manufacturers, exporters & distributors 1

12

PharmaCompass offers a list of Binimetinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Binimetinib manufacturer or Binimetinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Binimetinib manufacturer or Binimetinib supplier.

API | Excipient name

Binimetinib

Synonyms

606143-89-9, Mek162, Arry-162, Mektovi, Arry-438162, Mek-162

Cas Number

606143-89-9

Unique Ingredient Identifier (UNII)

181R97MR71

About Binimetinib

Binimetinib is an orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. Inhibition of MEK1/2 prevents the activation of MEK1/2 dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and an inhibition in production of various inflammatory cytokines including interleukin-1, -6 and tumor necrosis factor. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.

6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide Manufacturers

A 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, including repackagers and relabelers. The FDA regulates 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide Suppliers

A 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide supplier is an individual or a company that provides 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide active pharmaceutical ingredient (API) or 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide finished formulations upon request. The 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide suppliers may include 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide API manufacturers, exporters, distributors and traders.

click here to find a list of 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide USDMF

A 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide DMF (Drug Master File) is a document detailing the whole manufacturing process of 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide active pharmaceutical ingredient (API) in detail. Different forms of 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide DMFs exist exist since differing nations have different regulations, such as 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide DMF submitted to regulatory agencies in the US is known as a USDMF. 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide USDMF includes data on 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide suppliers with USDMF on PharmaCompass.

6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide WC

A 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide written confirmation (6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide WC) is an official document issued by a regulatory agency to a 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide manufacturer, verifying that the manufacturing facility of a 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide APIs or 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide finished pharmaceutical products to another nation, regulatory agencies frequently require a 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide WC (written confirmation) as part of the regulatory process.

click here to find a list of 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide suppliers with Written Confirmation (WC) on PharmaCompass.

6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide suppliers with NDC on PharmaCompass.

6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide GMP

6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide GMP manufacturer or 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide GMP API supplier for your needs.

6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide CoA

A 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide CoA (Certificate of Analysis) is a formal document that attests to 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide's compliance with 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide specifications and serves as a tool for batch-level quality control.

6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide CoA mostly includes findings from lab analyses of a specific batch. For each 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide may be tested according to a variety of international standards, such as European Pharmacopoeia (6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide EP), 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty